Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

1

About Wei Shang

Wei Shang Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Wei Shang News

Prognostic value of mean platelet volume to plateletcrit ratio in patients with osteosarcoma

Feb 17, 2019

Bo Gou, Hong Cao, Xinghua Cheng, Wei Shang, Mingqing Xu, Wei Qian Department of Orthopedics, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China Objective: The objective of this study was to investigate the prognostic value of preoperative mean platelet volume to plateletcrit (MPV/PCT) ratio in patients with osteosarcoma. Materials and methods: The retrospective study included 188 consecutive osteosarcoma patients who experienced neoadjuvant chemotherapy and surgical resection of tumor. The relationships between MPV/PCT and clinicopathological characteristics were analyzed. The Kaplan–Meier analysis and Cox regression proportional hazard model were applied to assess the prognostic value of MPV/PCT ratio. Results: MPV/PCT ratio was found to be significantly associated with platelet count, platelet distribution width, and PCT (all P<0.001). Kaplan–Meier analysis showed that high MPV/PCT ratio (≥43.58) was associated with a prolonged disease-free survival (DFS, P=0.035). The multivariate Cox revealed that only good chemotherapy response was an independent predictor of better DFS in the overall population. However, the stratification analysis showed that a high MPV/PCT ratio (≥43.58) was indicated as an independent prognostic factor for a favorable DFS (HR =0.137, 95%CI =0.029–0.644, P=0.012) in the male osteosarcoma patients but not in female patients. Conclusion: The high preoperative MPV/PCT ratio may serve as an independent prognostic factor for a favorable prognosis in male osteosarcoma patients. Further studies are needed to confirm the findings. Keywords: osteosarcoma, MPV/PCT, prognosis, platelet indices This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License . By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms .

Wei Shang Investments

1 Investments

Wei Shang has made 1 investments. Their latest investment was in The News Lens as part of their Series B on March 3, 2017.

CBI Logo

Wei Shang Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/23/2017

Series B

The News Lens

$2M

Yes

3

Date

3/23/2017

Round

Series B

Company

The News Lens

Amount

$2M

New?

Yes

Co-Investors

Sources

3

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.